The economic cost of substandard and falsified human medicines and cosmetics with banned ingredients represent a relatively large loss of scarce resources for a poor country like Tanzania. The increase in the quantities identified and the economic cost of these products over time could partly be due to improved regulatory capacity in terms of human resources, infrastructure and frequency of inspections.
ARTICLE SUMMARY

Strengths and limitations of this study
• This is the first study from a low-income country to use national representative data to estimate the economic cost of poor-quality medicines and cosmetics with banned ingredients over a ten-year period.
• We were able to identify the manufactures of substandard medicines and purported manufacturers for falsified medicines, which enabled us to isolate those whose products were more frequently found in the market.
• Some data particularly for cosmetics, were poorly recorded, which made it difficult to apply the proper costing approach of identification, quantification and valuation.
• The sharp increase in quantities and cost could be due to increased availability of data because of improved regulatory capacity and public awareness, as opposed to an absolute increase in the problem of poor-quality medicines and cosmetics.
• We were not able to include patient and health system costs for morbidities and mortalities associated with the use of poor-quality medicines and cosmetics with banned ingredients; hence, the study underestimates the actual economic cost. Guangzhou in southern China, and the amount of fake antimalarials was estimated to be enough to treat more than half of all annual malaria cases in Angola [1] . This example highlights the problem of substandard and falsified medicines (defined in Box 1) and its potential public health impact. Substandard and falsified medicines represent about 10% of all medicines sold in lowand middle-income countries [2] . Expenditure on these products in low-and middle-income countries is estimated at 30.5 billion US$ [2] . Falsified medicines represent one of the most lucrative criminal business and is estimated to be worth between 75-200 billion US$ [3] .
The use of substandard and falsified medicines and cosmetics with banned ingredients can have a tremendous negative impact on patient's health, that can range from serious harm to treatment failure that can lead to severe illness and death. It is estimated that between 90,000-200,000 malaria deaths could be prevented if all antimalarials were genuine [4, 5] . Sub-therapeutic plasma levels due to poor-quality medicines are strongly associated with emergence of antimicrobial resistance [6, 7] , hence increasing costs of treatment by switching from cheap firstline medicines to more expensive second-line medicines. The pharmaceutical industry is also a victim of falsified medicines, with annual losses estimated to be 45 million Euros, which consequently reduces investments in innovative research and development [8] .
Box 1: Definitions of substandard medicines, falsified medicines
Substandard medicines: According to WHO, these are genuine medicines that are authorized by the national medicines authorities, but which fails to meet national or international quality standards or specifications.
Falsified medicines: According to WHO, these represent deliberately and fraudulently labeled medicines with respect to identity, composition and source and may include products with the correct or wrong ingredients, without active ingredients, with insufficient active ingredients or with fake packaging [9] . Low-income countries are the prime targets of substandard and falsified medicines because regulatory agencies and law enforcement systems are relatively weak, accompanied by poorly regulated markets, and scarcity and/or erratic supply of basic medicines [10, 11] . Porous borders and complex supply chain system of pharmaceuticals also contributes to the problem. There is scarcity of national level data from low-income countries despite all evidences pointing towards an increasing problem of substandard and falsified medicines. Therefore, the objective of this study was to estimate the economic cost of substandard and falsified human medicines including cosmetics with banned ingredients in Tanzania from [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] .
METHODS
This costing study used an ingredient approach to estimate the economic cost of substandard and falsified human medicines and cosmetics with banned ingredients between 2005-2015. This method involves identification, quantification and valuation of individual items. Costing was done from the perspective of the regulatory authority and the pharmaceutical distributors. We did not include patient and health system costs because of scarcity of data on morbidities and mortalities likely to be caused by the use of these products.
Sources of data
We used data from the regulatory authority and the major importers and distributors of pharmaceuticals from 2005-2015. The regulatory authority usually keeps all the confiscation reports for poor-quality medicines and cosmetics that are collected during routine inspections of premises and major operations. The report usually contains among other information, the name of the premise, generic and brand names of the product, strength, physical description of the package and products, batch number, manufacturing and expiry dates as well as the quantities and sometimes an estimated value. Premises usually remain with the signed copy of the confiscation report. In this study we retrieved all the confiscation data that was available at the regulatory authority's headquarter and from its zonal offices. This data was complemented with that from the importers and distributors of pharmaceuticals and we were careful to avoid double counting. We also conducted a series of structured interviews with officials at the regulatory authority, importers and distributors to estimate operational cost incurred in the process of confiscation, withdraw of products from the market, storage, disposal and court cases.
Unregistered and expired medicines were not included.
Cost estimates
The study used the median buyer prices from the International Drug Price Indicator Guide (IDPIG) as a primary source of medicines prices and when they were not available the Medical Stores Price Catalogue of 2015/16 was used. In the absence of median buyer prices, the median supplier prices were used, with an inflation factor of 10% as recommended in the costing studies [12] . Prices from the IDPIG were inflated further by 10% to account for local opportunity costs.
Cost was calculated by multiplying the tallied quantities with unit prices for item. In some cases, only the estimated value of the items in the local currency were reported without information about the identity and quantities and this was common for cosmetics. In this case the total value in the local currency was first converted to US$ by using relevant exchange rate for that year before adjusting to the present value using relevant consumer price indices.
In addition, the study included storage costs, transportation costs, cost of disposal and cost charges for court cases. We measured the storage space (m 2 ) which was multiplied by 10 US$/m 2 which was the rate of rental charge used for warehouses by the Tanzania National Housing Corporation (NHC) and reported by most distributors of pharmaceuticals. Yearly storage costs were obtained by multiplying monthly rental charges by 12. Storage costs for the importers and distributors was considered only for the year when there was an incident of confiscation of substandard or falsified medicine or cosmetics with banned ingredients.
Ethical considerations
Ethical approval was obtained from the research and publication committee of the Muhimbili University of Health and Allied Sciences (MUHAS). The regulatory authority also granted research permission and issued an official letter to all local importers and distributors requesting them to make the relevant data available to the researchers and assuring them that the data requested will be used for research purpose only. A consent form was provided to all the interviewees and signed prior to interviews. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
RESULTS
Economic cost
The estimated economic cost of substandard and falsified human medicines and cosmetics with The same observation was also made for falsified medicines, in that falsified products bearing the name of the same purported manufacturer were consistently found on the market over several years. Example quinine and Sulphamethoxypyrazine/Pyrimethamine from manufacturer C and H, respectively, were identified circulating in the market over 3 years. This may imply that the culprits were not caught and continued to release the product into the market for several years, the sanctions were not deterrent, or the inspection and confiscation were not effective. 
Manufacturers of substandard and purported manufacturers of falsified medicines
DISCUSSION
It is difficult to estimate the actual economic cost of substandard and falsified medicines in any country not least in a low-income setting because data are usually not available [13] . However, using data from the regulatory authority, pharmaceutical importers and distributors we were able to estimate this burden in Tanzania Several studies have reported high levels of antibiotic resistance in Tanzania especially for commonly used and cheap antibiotics [15] [16] [17] [18] , which has prompted the government to develop a national action plan to curb antimicrobial resistance [19] .
Policy implications
The quantities and the economic cost of substandard and falsified human medicines including cosmetics with banned ingredients in Tanzania over the past ten years is alarming. Policy-makers in Tanzania need to improve the existing post-marketing surveillance (PMS) and pharmacovigillance (PV) system for effective prevention, detection and response to poor-quality products, adverse effects and other medicines-related health and economic problems. An effective PMS and PV systems are essential components of any healthcare system. However, in low-income countries including Tanzania such systems are weak or non-existent, hence health problems associated with the use of substandard and falsified medicines such as adverse reactions, ineffective treatment or even death often go undetected.
The government and policy makers need to provide more resources to the regulatory authorities in Tanzania to enhance supervision and inspection to ensure integrity of the supply chain of pharmaceuticals both in the public and the private sectors. Limited access to affordable essential medicines in the public health system has resulted in the opening of a large number of private retail pharmacies and small accredited drug dispensing outlets in the country, which have proved very difficult to control [20] . As a consequence, malpractices are common including selling medicines without prescriptions, stocking medicines from unofficial sources, poor documentation and hiring of people without the required qualifications, making them the prime target for the business of substandard and falsified medicines [13] .
The fact that some substandard and falsified human medicines from certain manufacturers were confiscated over several years raise a more serious concern. This was observed for example for falsified quinine tablets purporting to be from manufacturer B and C, and sulphamethoxypyrazine/pyrimethamine tablets mimicking that of manufacturer H. There could be several reasons behind this; first it could indicate a sign of insufficient inspection or ineffective removal of the product from the market. Secondly, it could be that the products were easy to be falsified and smuggled into the country; thirdly, poor compliance with Good
Manufacturing Practices and lastly it could also imply that the culprits were not identified, or if identified the sanctions were not deterrent, hence continued to supply the products.
Strengths and limitations
To the best of our knowledge, this is the first study to systematically combine data retrieved from the regulatory authority, importers and distributors of pharmaceuticals to estimate the economic cost of substandard and falsified medicines and cosmetics with banned ingredients in a lowincome country. The data also facilitated the identification of the manufactures of substandard medicines and manufacturers whose products were falsified, which enabled us to isolate those whose products were repetitively found circulating in the market. However, this study has several limitations. Firstly, we did not have morbidity and mortality data to facilitate the inclusion of patient and health system costs associated with the use of poor-quality medicines and cosmetics with banned ingredients. This means our study underestimates the actual economic cost of these products. Secondly, some data was poorly recorded, which made it difficult to follow the proper costing procedure of identification, quantification and valuation.
CONCLUSION
The economic cost of substandard and falsified human medicines and cosmetics with banned ingredients represent a relatively large loss of scarce resources for a low-income country like
Tanzania. The increase in the quantities identified and the economic cost of these products over time could partly be due to improved regulatory capacity in terms of human resources, infrastructure, frequency of inspections, implementation of post-marketing surveillance, establishment of more zone offices, and strengthened quality control laboratory with WHO prequalification. These improvements in addition to efforts by the authority and the government to increase awareness among stakeholders could have positive and sustainable impact in the longer term. However, proliferation of retail drug outlets that are difficult to regulate and ineffective control of many porous borders will continue to be a challenge to the regulatory authority. Policy-makers should make the fight against substandard and falsified medicines a national priority agenda, including development of national strategies and action plans.
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Conclusion:
The economic cost of substandard and falsified human medicines and cosmetics with banned ingredients represent a relatively large loss of scarce resources for a poor country like Tanzania. We believe that the observed increase in the quantities and the economic cost of these products over time could partly be due to the improvement in the regulatory capacity in terms of human resources, infrastructure and frequency of inspections. 
ARTICLE SUMMARY
Strengths and limitations of this study
• We could not determine the reasons for the increase in quantities and cost over time, but we believe this could be due to increased availability of data because of improved regulatory capacity and public awareness, as opposed to an absolute increase in the amount of poor-quality medicines and cosmetics.
• We were not able to include patient and health system costs for morbidities and mortalities associated with the use of poor-quality medicines and cosmetics with banned ingredients; hence, the study underestimates the actual economic cost. The use of substandard and falsified medicines and cosmetics with banned ingredients can have a tremendous negative impact on patient's health, that can range from serious harm to treatment failure that can lead to severe illness and death. It is estimated that between 90,000-200,000 malaria deaths could be prevented if all antimalarials were genuine [4, 5] . Sub-therapeutic plasma levels due to poor-quality medicines are strongly associated with emergence of antimicrobial resistance [6, 7] , hence increasing costs of treatment by switching from cheap firstline medicines to more expensive second-line medicines. The pharmaceutical industry is also a victim of falsified medicines, with annual losses estimated at 45 million Euros, which consequently reduces investments in innovative research and development [8] .
Box 1: Definitions of substandard medicines, falsified medicines
METHODS
Sources of data
We used data from the regulatory authority and the major importers and distributors of pharmaceuticals from 2005-2015. The regulatory authority usually keeps all the confiscation reports for poor-quality medicines and banned cosmetics that are collected during routine inspections of premises and major operations. The report usually contains among other information, the name of the premise, generic and brand names of the product, strength, physical description of the package and products, batch number, manufacturing and expiry dates as well as the quantities and sometimes an estimated value. Premises usually remain with the signed copy of the confiscation report. In this study we retrieved all the confiscation data that was available at the regulatory authority's headquarter and from its zonal offices. We also used confiscation report forms from the importers and distributors of pharmaceuticals to complement data from the regulatory authority. This means, in case the report forms were not filed at the regulatory authority, copies that were available at the importers and distributors offices were used. We were careful to avoid double counting. We also conducted a series of structured interviews with some officials at the regulatory authority and the importers and distributors of pharmaceuticals to estimate operational cost incurred in the process of confiscation, withdraw of products from the market, storage, disposal and proceedings of court cases. Unregistered medicines do not undergo evaluation and approval by the regulatory authority; hence, together with the expired human medicines were not included in the cost analysis.
Cost estimations
The study used the median buyer prices from the International Drug Price Indicator Guide (IDPIG) as a primary source of medicines prices and when they were not available the Tanzanian
Medical Stores Price Catalogue of 2015/16 was used. In the absence of median buyer prices, the median supplier prices were used, with an inflation factor of 10% as recommended in the costing studies [12] . Prices from the IDPIG were inflated further by 10% to account for local opportunity costs. Cost was calculated by multiplying the tallied quantities with unit prices for each item. In some cases, only the estimated value of the items in the local currency were reported without information about the identity and quantities and this was common for cosmetics. In this case the total value in the local currency was first converted to US$ by using relevant exchange rate for that year before adjusting to the present value using relevant consumer price indices.
Once the yearly value of falsified medicines, substandard medicines and cosmetics with banned ingredients were estimated, we added other/operational costs which included the storage costs, transportation costs, cost of disposal and cost charges for court cases to arrive to the annual total cost. We measured the storage area (m 2 ) which was multiplied by 10 US$/m 2 which was the rate of rental charge used for warehouses by the Tanzania National Housing Corporation (NHC) and reported by most distributors of pharmaceuticals. Yearly storage costs were obtained by multiplying monthly rental charges by 12. Storage costs for the importers and distributors was considered only for the year when there was an incident of confiscation of substandard or falsified medicine or cosmetics with banned ingredients.
Ethical considerations
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University of Health and Allied Sciences (MUHAS). The regulatory authority also granted
research permission and issued an official letter to all local importers and distributors requesting them to make the relevant data available to the researchers and assuring them that the data requested will be used for research purpose only. A consent form was provided to all the interviewees and signed prior to interviews.
Patient and Public Involvement
Patients were not directly involved in the study. However, the research question and outcome measures were informed with concerns for safety and economic wellbeing of patients and the public. Poor-quality medicines and banned cosmetics not only contribute to increased morbidity and mortality but also can cause substantial economic loss to patients, families, health systems and everyone involved with the sale and manufacture of pharmaceuticals.
RESULTS
Economic cost
The estimated economic cost of substandard and falsified human medicines and cosmetics with (Table 1) . Between for manufacturer E, M and B for quinine, paracetamol and aminophylline, respectively.
Manufacturers of substandard and purported manufacturers of falsified medicines
The same observation was also made for falsified medicines, in that falsified products bearing the name of the same purported manufacturer were consistently found on the market over several years. Example quinine and sulfamethoxypyrazine-pyrimethamine from manufacturer C and H, respectively, were identified circulating in the market over 3 years. 
DISCUSSION
It is difficult to estimate the actual economic cost of substandard and falsified medicines in any country not least in a low-income setting because data are usually not available [13] . However, using data from the regulatory authority, pharmaceutical importers and distributors we were able to estimate this burden in Tanzania [15] [16] [17] [18] , which has prompted the government to develop a national action plan to curb antimicrobial resistance [19] .
Policy implications
The quantities and the economic cost of substandard and falsified human medicines including cosmetics with banned ingredients in Tanzania over the past ten years is alarming. Policy-makers in Tanzania need to continue to improve the existing post-marketing surveillance (PMS) and pharmacovigillance (PV) system for effective prevention, detection and response to poor-quality products, adverse effects and other medicines-related health and economic problems. An effective PMS and PV systems are essential components of any healthcare system. However, in low-income countries including Tanzania such systems are weak or non-existent, hence health problems associated with the use of substandard and falsified medicines such as adverse reactions, ineffective treatment or even death often go undetected.
The government and policy makers need to provide more resources to the regulatory authorities in Tanzania to enhance supervision and inspection to ensure integrity of the supply chain of pharmaceuticals both in the public and the private sectors. Limited access to affordable essential medicines in the public health system has resulted in the opening of many private retail pharmacies and small accredited drug dispensing outlets in the country, which have proved very difficult to control [20] . As a consequence, malpractices are common including selling medicines without prescriptions, stocking medicines from unofficial sources, poor documentation and hiring of people without the required qualifications, making them the prime target for the business of substandard and falsified medicines [13] . The fact that some substandard and falsified human medicines from certain manufacturers were confiscated over several years raise a more serious concern. This was observed for example for falsified quinine tablets purporting to be from manufacturer B and C, and sulfamethoxypyrazinepyrimethamine tablets mimicking that of manufacturer H. There could be several reasons behind this; first it could indicate a sign of insufficient inspection or ineffective removal of the product from the market. Secondly, it could be that the products were easy to be falsified and smuggled into the country; thirdly, poor compliance with Good Manufacturing Practices and lastly it could also imply that the culprits were not identified, or if identified the sanctions were not deterrent, hence continued to supply the products.
Strengths and limitations
Thirdly, we were not able to determine the reasons behind the increasing quantities and costs.
However, we believe this could be due to improvement in regulatory capacity and public awareness rather than an absolute increase in the amount of poor-quality medicines and banned cosmetics.
CONCLUSION
The economic cost of substandard and falsified human medicines and cosmetics with banned ingredients represent a relatively large loss of scarce resources for a low-income country like Tanzania. The increase in the quantities identified and the economic cost of these products over time could partly be due to improved regulatory capacity in terms of human resources, infrastructure, frequency of inspections, implementation of post-marketing surveillance, establishment of more zone offices, and strengthened quality control laboratory with WHO prequalification. These improvements in addition to efforts by the authority and the government to increase awareness among stakeholders could have positive and sustainable impact in the longer term. However, proliferation of retail drug outlets that are difficult to regulate and ineffective control of many porous borders will continue to be a challenge to the regulatory authority. Policy-makers should make the fight against substandard and falsified medicines a national priority agenda, including development of national strategies and action plans.
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